Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.11 CHF | -1.00% | -2.96% | +7.35% |
05-27 | Novartis: positive phase III results in C3G | CF |
05-27 | Novartis: presented results for kidney disease | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.35% | 205B | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B | |
-1.31% | 122B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis Says Kisqali Results in Better Progression-Free Survival Than Chemotherapy in Phase 2 Breast Cancer Trial